BIOGEN INC. Unrealized Gain (Loss) on Derivatives
BIOGEN INC. (BIIB) reported Unrealized Gain (Loss) on Derivatives of -$14.70 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2026-04-29
- BIOGEN INC. unrealized gain (loss) on derivatives for the quarter ending 2026-03-31 was -$14.70M.
- BIOGEN INC. unrealized gain (loss) on derivatives for the quarter ending 2025-09-30 was $31.80M.
- BIOGEN INC. unrealized gain (loss) on derivatives for the quarter ending 2025-06-30 was -$61.90M.
- BIOGEN INC. unrealized gain (loss) on derivatives for the quarter ending 2025-03-31 was -$73.30M, a 245.73% decline year-over-year.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 3 month as first filed | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 6 month as first filed | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 9 month as first filed |
|---|---|---|---|---|---|---|
| 2026-03-31 | -$14.70M 10-Q · filed 2026-04-29 | |||||
| 2025-09-30 | $31.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$30.10M derived: sum of 2 quarters · filed 2025-10-30 | -$103.40M 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | -$61.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$135.20M 10-Q · filed 2025-07-31 | ||||
| 2025-03-31 | -$73.30M 10-Q · filed 2026-04-29 | -$14.10M 10-Q · filed 2025-05-01 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $50.30M 10-Q · filed 2025-10-30 | -$41.50M 10-Q · filed 2024-10-30 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $50.30M 10-Q · filed 2025-07-31 | $3.40M 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $50.30M 10-Q · filed 2025-05-01 | |||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$34.80M 10-Q · filed 2024-10-30 | ||||
| 2023-06-30 | -$34.80M 10-Q · filed 2024-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |